Archives of Hellenic Medicine

Last update:

01-Aug-2025

Arch Hellen Med, 42(5), September-October 2025, 652-659

ORIGINAL PAPER

Major molecular responses in newly diagnosed chronic myeloid leukemia
A meta-analysis of one-year outcomes of dasatinib, imatinib, and nilotinib treatments

F. Widianto,¹ J.K. Fajar²
¹Department of Internal Medicine, RSUD, Dr Mohammad Zyn, Sampang
²Center of Medical Research, Deka Institute, Malang, Indonesia

OBJECTIVE Τo assess the effectiveness of imatinib, dasatinib, and nilotinib in achieving a major molecular response at 12 months (MMR12) as first-line treatments for chronic phase chronic myeloid leukemia (CML).

METHOD A meta-analysis was performed utilizing data extracted from PubMed, Embase, and Scopus, covering the period from May to June 2024. Information on MMR12 from each study was compiled to estimate effect sizes using the Mantel-Haenszel method. The statistical analysis was conducted with Review Manager 5.1.

RESULTS The analysis included a total of 27 articles. Our findings indicated that dasatinib exhibited higher efficacy in achieving MMR12 compared to imatinib (odds ratio [OR]: 2.03; 95% confidence interval [CI]: 1.77−2.32; p<0.0001). Additionally, nilotinib was found to be more effective than imatinib for treating chronic phase CML (OR: 2.75; 95% CI: 2.41−3.18; p<0.0001). However, dasatinib and nilotinib showed similar outcomes in the treatment of CML patients (OR: 0.74; 95% CI: 0.52−1.05; p=0.0900).

CONCLUSIONS Dasatinib and nilotinib exhibit the most promising efficacy as first-line treatments for chronic phase CML based on the achievement of MMR12.

Key words: Chronic myeloid leukemia, Dasatinib, Imatinib, Major molecular response at 12 months, Nilotinib.